Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share

Royalty Pharma has declared a dividend of $0.22 per Class A ordinary share for the third quarter of 2025. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. This is part of Royalty Pharma's ongoing commitment to funding innovation in the biopharmaceutical industry.

Royalty Pharma plc (NASDAQ: RPRX) has announced a dividend of $0.22 per Class A ordinary share for the third quarter of 2025. The dividend is scheduled to be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025 [2].

This latest dividend payment is part of Royalty Pharma's ongoing commitment to funding innovation in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovations, collaborating with various entities including academic institutions, research hospitals, and pharmaceutical companies [2].

Institutional investors and hedge funds have shown significant interest in Royalty Pharma's stock. In the first quarter of 2025, several institutions increased their stakes in the company, including Merit Financial Group LLC, Yousif Capital Management LLC, Asset Management One Co. Ltd., Amalgamated Bank, and M&T Bank Corp [1].

Royalty Pharma's stock has been performing well, hitting a new 52-week high during trading on Wednesday, July 16, 2025. The stock traded as high as $36.69 and last traded at $36.51, with a volume of 2.817 million shares trading hands. The company's financial health is reflected in its strong fundamentals, including a debt-to-equity ratio of 0.68, a quick ratio of 1.56, and a current ratio of 1.56 [1].

Analysts have provided mixed ratings for Royalty Pharma's stock. While Citigroup and Morgan Stanley have maintained positive ratings, Wall Street Zen downgraded the stock from a "buy" to a "hold" rating [1]. Despite the mixed analyst ratings, the stock has an average rating of "Buy" and an average price target of $48.33 [1].

The company's recent earnings report highlighted strong financial performance. Royalty Pharma reported earnings per share (EPS) of $1.06 for the quarter ending May 8, 2025, surpassing analysts' consensus estimates by $0.07. The company also boasted a return on equity of 24.71% and a net margin of 48.23% [1].

In conclusion, Royalty Pharma's dividend announcement is a positive development for shareholders, reflecting the company's commitment to innovation and strong financial performance. The company's diverse portfolio of royalties and strategic partnerships position it well for continued growth in the biopharmaceutical industry.

References:
[1] https://www.marketbeat.com/instant-alerts/royalty-pharma-nasdaqrprx-hits-new-12-month-high-still-a-buy-2025-07-16/
[2] https://www.stocktitan.net/news/RPRX/royalty-pharma-declares-third-quarter-2025-eiym7sqonjkp.html